» Articles » PMID: 33453607

EF24 Induces Ferroptosis in Osteosarcoma Cells Through HMOX1

Overview
Date 2021 Jan 16
PMID 33453607
Citations 72
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: EF24, a synthetic analogue of curcumin, was developed as an anti-tumor compound to induce apoptosis, inhibit proliferation and metastasis in various cancers. However, whether EF24 induces ferroptosis in osteosarcoma cells or not, and its underlying mechanism remains largely elusive.

Methods: After EF24 combining with or without other compounds treatments, mRNA expression profiles were proceeded by RNA sequencing. Cytotoxicity was measured by cell counting kit-8 assay. Cell death was quantified by flow cytometer. Gene expression was quantified by real-time PCR. Protein level was detected by western blot. Malonydialdehyde (MDA) level was measured by lipid peroxidation MDA assay kit. Reactive oxygen species (ROS) level was measured by ROS Assay Kit. Ferric ion was measured by Iron Assay kit.

Results: EF24 significantly induced cell death in osteosarcoma cell lines, and this effect was significantly reversed by ferrostatin-1, but not Z-VAD(Ome)-FMK, MRT68921 or necrosulfonamide. EF24 significantly increased MDA level, ROS level and intracellular ferric ion level, these effects were significantly attenuated by ferrostatin-1. EF24 upregulated HMOX1 expression in a dose dependent manner, overexpression of HMOX1 facilitated EF24 to induce ferroptosis in osteosarcoma cell lines. HMOX1 knockdown attenuated EF24-induced cytotoxicity and attenuated EF24-induced inhibition of Glutathione Peroxidase 4 (GPX4) expression.

Conclusion: Our results showed that EF24 upregulated HMOX1 to suppress GPX4 expression to induce ferroptosis by increasing MDA level, ROS level and intracellular ferric ion level. Thus, EF24 might serve as a potential agent for the treatment of HMOX1-positive osteosarcoma patients.

Citing Articles

Ferroptosis-Related Transcriptional Level Changes and the Role of CIRBP in Glioblastoma Cells Ferroptosis.

Yang Z, Zhang T, Zhu X, Zhang X Biomedicines. 2025; 13(1).

PMID: 39857625 PMC: 11761263. DOI: 10.3390/biomedicines13010041.


Polydatin-Induced Shift of Redox Balance and Its Anti-Cancer Impact on Human Osteosarcoma Cells.

Cimmino A, Gioia M, Clementi M, Faraoni I, Marini S, Ciaccio C Curr Issues Mol Biol. 2025; 47(1).

PMID: 39852136 PMC: 11764470. DOI: 10.3390/cimb47010021.


Using β-Elemene to reduce stemness and drug resistance in osteosarcoma: A focus on the AKT/FOXO1 signaling pathway and immune modulation.

Zhang S, Xing Z, Ke J J Bone Oncol. 2025; 50():100655.

PMID: 39850453 PMC: 11755076. DOI: 10.1016/j.jbo.2024.100655.


Naringenin induces ferroptosis in osteosarcoma cells through the STAT3-MGST2 signaling pathway.

Li Y, Bai X J Bone Oncol. 2025; 50():100657.

PMID: 39835176 PMC: 11743371. DOI: 10.1016/j.jbo.2024.100657.


Melanoma bone metastasis-induced osteocyte ferroptosis via the HIF1α-HMOX1 axis.

Jia Y, Li R, Li Y, Kachler K, Meng X, Giessl A Bone Res. 2025; 13(1):9.

PMID: 39814705 PMC: 11735842. DOI: 10.1038/s41413-024-00384-y.